Iteos Therapeutics Inc (ITOS) - News Archive

Incyclix Bio has recently announced promising interim results from its ongoing Phase 1/2 clinical trial assessing the efficacy of INX-315 in patients with CDK4/6 inhibitor-resistant ER+/HER2- breast cancer or CCNE1-ampl...

Inupadenant, developed by iTeos Therapeutics, has recently gained attention following its presentation of interim clinical trial data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress. This in...

iTeos Therapeutics Reports Promising Results in Lung Cancer Study Amid Market ChallengesiTeos Therapeutics Inc. has recently announced encouraging findings from its GALAXIES Lung-201 study, which investigated the combin...

iTeos Therapeutics, a clinical-stage biopharmaceutical company dedicated to revolutionizing immuno-oncology treatment options, has recently made significant progress in its pursuit of developing novel therapeutics. The...

In a groundbreaking collaboration, iTeos Therapeutics, Inc. (Nasdaq: ITOS) and GSK have embarked on an ambitious endeavor to tackle one of the most formidable challenges in oncology: non-small cell lung cancer (NSCLC)....

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical trailblazer in the field of immuno-oncology, announced publicly the poster presentation of the preclinical data on their innovative development, EOS-984, at t...